

Ruthenium-peptide conjugates for targeted phototherapy

Zhang, I.

Citation

Zhang, I. (2023, July 4). Ruthenium-peptide conjugates for targeted phototherapy. Retrieved from https://hdl.handle.net/1887/3628436

Version: Publisher's Version

Licence agreement concerning inclusion

License: of doctoral thesis in the Institutional

Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/3628436

Note: To cite this publication please use the final published version (if applicable).

Stellingen

behorende bij het proefschrift

Ruthenium-Peptide Conjugates for Targeted Phototherapy

- Peptide conjugation to anticancer metallodrugs is an effective strategy to improve their biocompatibility and tumor selectivity at low synthetic costs. (*This thesis, Chapter 2, 3,* 4 & 5).
- 2. When designing ruthenium-peptide conjugates for photoactivated chemotherapy, a balance should be made between steric hindrance and electronic effects to achieve both good dark stability and high photosubstitution efficiency. (*This thesis, Chapter 2*).
- A ruthenium-based prodrug for photoactivated chemotherapy that is initially incapable
 of producing singlet oxygen can become a good dioxygen photosynthesizer upon
 reaction with biomolecules and subsequent light activation. (*This thesis, Chapter 4 & 5*).
- 4. *In vivo* studies using mice models are time-consuming and expensive, zebrafish models are better choices for researchers who focus primarily on the biodistribution of drugs. (*This thesis, Chapter 3, 4 & 6*).
- Learning from the wisdom of nature is of great significance to the development of science. (Lee, L. P., et al. Science 310, 1148-1150 (2005); Mann, J. Nature Reviews Cancer 2, 143-148 (2002)).
- The combination of PACT and/or PDT with other therapeutic modalities is able to
 provide opportunities to exploit the advantages of each of them, and offset their
 disadvantages. (Chen, X., et al. Nature reviews Clinical oncology 17, 657-674 (2020);
 McFarland, S. A., et al. Journal of the American Chemical Society 144, 9543-9547
 (2021)).

7. Further development and novel applications of photoactivated chemotherapy requires

collaborative efforts from different disciplines. (Agostinis, P., et al. CA: a cancer journal for clinicians 61, 250-281 (2011); Poynton, F. E., et al. Chemical Society

Reviews 46, 7706-7756 (2017)).

8. Prolonging drug retention time is equally important as improving its accumulation

efficiency in tumors. (Oku, N., et al. Cancer letters 167, 49-56 (2001)).

9. A universal cell-viability assay for metal-based anticancer complexes is needed.

10. Better think twice and find good collaborators when performing research, as the number

of experiments that can be performed during a PhD thesis is finite.

11. Medicinal chemists should read clinical articles.

12. The honor gained with a PhD degree does not only belong to yourself.

Liyan Zhang

Leiden, July 2023